Bionano Genomics, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-5
Book Value Per Share
$8
Free Cash Flow Per Share
$-3
Cash Per Share
$1
Revenue Per Share
$5
OCF Per Share
$-3
Return on Equity
-66.2%
Return on Assets
-35.1%
Return on Invested Capital
-66.0%
Debt to Equity
—
Current Ratio
1.98
Quick Ratio
1.64
Asset Turnover
0.38
Days Sales Outstanding
66.58
Days Payables Outstanding
133.16
Days Inventory On Hand
186.47
Cash Conversion Cycle
119.89
R&D / Revenue
39.9%
SBC / Revenue
15.9%
Capex / Revenue
—
Working Capital
$22M
Net Current Asset Value
$16M
Invested Capital
$44M
OCF / Net Income
0.62
FCF / Net Income
0.62
Accruals Ratio (Sloan)
-13.7%
Net Debt
$-3M
Net Debt / EBITDA
0.13
Interest Coverage
-30.01
Cash Coverage
-14.71
Capex Coverage
—
Tangible Common Equity
$40M
TCE / Total Assets
54.5%
Goodwill / Total Assets
—
NOPAT
$-26M
Cash ROIC
-41.0%
WC / Revenue
78.7%
Capex / D&A
—
Reinvestment Rate
28.6%
Asset Growth vs Revenue Growth
3.3%
Revenue 5Y CAGR
27.4%
Book Value 5Y CAGR
4.8%
Stock Price (FY-end)
$2
Market Cap
$8M
P/S Ratio
0.29
P/B Ratio
0.19
P/TB Ratio
0.21
Enterprise Value
$5M
EV / Sales
0.19
FCF Yield
-196.2%
Shareholder Yield
-54.4%
R&D Yield
136.5%
Shares Variation (YoY)
328.4%
Beta (5Y)
1.86
Cost of Equity
13.8%
Cost of Debt (after tax)
—
52W High
$19
52W Low
$1
Trailing Return 1Y
-87.9%
Trailing Return 5Y
-99.7%
F-Score (Piotroski)
4.00
M-Score (Beneish)
—
Z-Score (Altman)
-14.26
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
Bionano Genomics, Inc. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2024 | FY2025 |
|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% |
| State & Local Income Taxes | -0.33% | -0.67% |
| Foreign Rate Differential | 0.05% | -0.10% |
| Other Adjustments | 0.75% | -0.52% |
| R&D Tax Credits | 0.13% | -0.89% |
| SBC (Nondeductible) | -1.53% | -2.86% |
| Valuation Allowance Change | -24.09% | -20.86% |
| Effective Tax Rate | -0.04% | -0.25% |
Cash vs Accrual
| Item | FY2024 | FY2025 |
|---|---|---|
| Income Tax Expense (Accrual) | $33.0K | $67.0K |
| Income Taxes Paid (Cash) | $54.0K | $119.0K |
Bionano Genomics, Inc. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.